217 patients were treated with camrelizumab 3 mg/kg intravenously every 2 or 3 weeks. Treatment beyond first RECIST-defined progression (TBP) was allowed according to protocol-specified criteria.Results: At data cutoff (Dec 16, 2019; median duration of follow-up, 13.2 months [IQR 5.7e25.8]), 14 (43.8%) of the 32 responses per blinded independent central review were ongoing. The median duration of response (DoR) was not reached (range 2.5e30.5 + months). The estimated DoR rates at 12, 18, and 24 months were 68.3% (95% CI 47.7e82.2), 59.8% (95% CI 38.8e75.6), and 53.1% (95% CI 31.0e 71.0), respectively. Deaths were reported for 146 (67.3%) of the 217 patients. The median OS was 14.2 months (95% CI 11.5e16.3). The 18-and 24-month OS rates were 41.3% (95% CI 34.6e47.9) and 33.7% (95% CI 27.3e40.2), respectively. In total, 172 patients experienced RECIST-defined progression per investigator assessment, of whom 102 received TBP while 70 did not (non-TBP). The median OS was 16.9 months (95% CI 13.3e22.6) in the TBP group vs. 9.4 months (95% CI 5.8e14.8) in the non-TBP group, and the 18-and 24-month OS rates were 47.5% (95% CI 37.3e 56.9) vs. 33.1% (95% CI 22.3e44.3) and 38.8% (95% CI 29.2e48.4) vs 23.2% (95% CI 13.8e34.1), respectively. No new safety signals of camrelizumab were observed in the TBP group.Conclusions: With prolonged follow-up, camrelizumab continues to demonstrate durable response and long survival in pre-treated advanced HCC patients with manageable toxicities, especially in those who continued treatment beyond RECISTdefined first progression demonstrated.

No abstract

No abstract

No abstract

Background: Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) showed encouraging antitumor activity in solid tumors. Here, we report the results of 3 cohorts of advanced G/GEJ adenocarcinoma, ESCC and NEC of an ongoing, multi-cohort, phase 2 study of S + T (NCT04169672).Methods: Patients (pts) with histologically confirmed G/GEJ adenocarcinoma or advanced/metastatic ESCC or advanced NEC who progressed after 1L systemic chemotherapy were enrolled in cohorts A, B, C, respectively. Eligible pts received 21day cycles of S (250 mg orally QD) plus T (240 mg IV, Q3W). The primary endpoint was objective response rate (ORR) per RECIST 1.1.